Search

Displaying results 481 - 490 of 4600 in total
  1. Drug

    Citalopram

    go.drugbank.com/drugs/DB00215
    ApprovedInvestigational

    [A261316] Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older.[L5230]

  2. Drug

    Trifarotene

    go.drugbank.com/drugs/DB12808
    ApprovedInvestigational

    Trifarotene is considered the first of the "fourth-generation" retinoids due to its uniquely selective activity - this selectivity appears to confer improved efficacy and reduced side effects as compared to older

  3. Drug

    Dabrafenib

    go.drugbank.com/drugs/DB08912
    ApprovedInvestigational

    [L41955] It was also used for metastatic non-small cell lung cancer with the same mutation. … [L41955] In May 2018, Tafinlar (dabrafenib), in combination with Mekinist ([DB08911]), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.[L41955]

  4. Drug

    Isavuconazonium

    go.drugbank.com/drugs/DB06636
    ApprovedInvestigational

    [A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications.[L49251] … , marketed by Astellas under the brand Cresemba.

  5. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    [A286054] This off-label practice was formalized with the approval of Lytenava (bevacizumab-vikg in the US; bevacizumab gamma in the EU/UK), the first ophthalmic formulation of bevacizumab developed specifically … [A192888,A192939] The same anti-VEGF activity that suppresses tumor angiogenesis also suppresses the pathological choroidal and retinal neovascularization that drives vision loss in retinal disease, giving

  6. Drug

    Lirentelimab

    go.drugbank.com/drugs/DB16728
    Investigational

    Lirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).

    Synonyms: IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS SIALIC ACID-BINDING IG-LIKE LECTIN 8 (SIALOADHESIN FAMILY MEMBER 2, SIGLEC-8, SAF-2))HUMANIZED MOUSE MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (VH (HOMO
  7. Drug

    Ustekinumab

    go.drugbank.com/drugs/DB05679
    ApprovedInvestigational

    In October 2019, it was also approved by the FDA for use to manage moderately to severely active ulcerative colitis in adults. … [A187346] The therapeutic use of the drug started in Canada, the US, and Europe since 2009 when it was first approved for the treatment of adult patients with moderate to severe plaque psoriasis and

  8. Drug

    Lauric acid

    go.drugbank.com/drugs/DB03017
    Approved

    Lauric acid is an inexpensive, non-toxic and safe to handle compound often used in laboratory investigations of melting-point depression. … Lauric acid is a solid at room temperature but melts easily in boiling water, so liquid lauric acid can be treated with various solutes and used to determine their molecular masses.

  9. Drug

    Trofinetide

    go.drugbank.com/drugs/DB06045
    Approved

    [A258438] Trofinetide was approved by the FDA on March 10, 2023, for the treatment of Rett syndrome,[L45718,L45748] which is an X-linked neurodevelopmental disorder characterized by a range of cognitive … [A258438] Trofinetide is believed to work by reducing inflammation and apoptosis of neurons.

  10. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction. … [L56053] By substituting the native manganese cofactor with cobalt to enhance catalytic activity, this agent effectively degrades elevated plasma arginine into ornithine and urea, thereby mitigating the